ストックスクリーナーアプリを入手
179.14
0.07%
0.13
アフターアワーズ：
179.99
0.85
+0.47%
前日終値:
$179.01
開ける：
$178.47
24時間の取引高:
10.88M
Relative Volume:
2.14
時価総額：
$125.93B
収益：
$24.78B
当期純損益:
$3.68B
株価収益率:
34.62
EPS:
5.1743
ネットキャッシュフロー:
$5.29B
1週間 パフォーマンス:
-10.78%
1か月 パフォーマンス:
+0.53%
6か月 パフォーマンス:
-25.38%
1年 パフォーマンス:
-5.67%
1日の値動き範囲:
$173.00
$180.12
1週間の範囲:
$165.75
$206.59
52週間の値動き範囲:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
名前
Danaher Corp
セクター
電話
(202) 828-0850
住所
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, NTRA, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
179.14 | 125.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
526.46 | 194.53B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
545.00 | 43.58B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
264.22 | 38.26B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
133.46 | 37.52B | 7.23B | 1.41B | 1.09B | 4.979 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Goldman | Buy |
| 2025-12-02 | 開始されました | Morgan Stanley | Overweight |
| 2025-10-08 | ダウングレード | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-03-21 | アップグレード | Goldman | Neutral → Buy |
| 2025-03-14 | アップグレード | Stifel | Hold → Buy |
| 2025-02-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-19 | 開始されました | Guggenheim | Buy |
| 2024-12-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-31 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | 開始されました | Stephens | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-17 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-01-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-18 | 開始されました | HSBC Securities | Hold |
| 2023-12-13 | 再開されました | Wolfe Research | Peer Perform |
| 2023-12-07 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-05-01 | 開始されました | SVB Securities | Outperform |
| 2023-04-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-10-24 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-08-17 | 再開されました | Bernstein | Outperform |
| 2022-07-20 | 開始されました | UBS | Buy |
| 2022-06-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | 開始されました | Bernstein | Outperform |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-09-10 | 繰り返されました | BofA Securities | Buy |
| 2021-08-05 | 再開されました | Credit Suisse | Outperform |
| 2021-07-23 | 繰り返されました | Goldman | Buy |
| 2021-07-16 | 開始されました | The Benchmark Company | Buy |
| 2021-04-07 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-03 | 再開されました | Barclays | Overweight |
| 2020-12-02 | 開始されました | Goldman | Buy |
| 2020-11-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | 繰り返されました | Needham | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-11-15 | 再開されました | Stifel | Hold |
| 2019-10-28 | 繰り返されました | Needham | Buy |
| 2019-10-14 | 再開されました | Credit Suisse | Outperform |
| 2019-07-19 | 繰り返されました | Needham | Buy |
| 2019-06-11 | 開始されました | Piper Jaffray | Neutral |
| 2019-05-30 | 開始されました | Wolfe Research | Outperform |
| 2019-04-17 | 繰り返されました | Needham | Buy |
| 2019-02-28 | 繰り返されました | Needham | Buy |
| 2019-02-25 | アップグレード | Janney | Neutral → Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-04-20 | 繰り返されました | Stifel | Buy |
すべてを表示
Danaher Corp (DHR) 最新ニュース
Danaher Corporation (DHR) technical analysisDanaher (NYSE:DHR) - Benzinga
DHR Maintained by Wells Fargo -- Price Target Lowered to $195 - GuruFocus
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C - GuruFocus
DHR Maintained by Guggenheim -- Price Target Lowered to $200 - GuruFocus
Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says - marketscreener.com
TD Cowen cuts Danaher stock price target on bioproduction timing By Investing.com - Investing.com Canada
TD Cowen cuts Danaher stock price target on bioproduction timing - Investing.com
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6% - AlphaStreet
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Cepheid to Unveil Third-Generation GeneXpert® System at ADLM 2026, Advancing Molecular Diagnostic Capabilities - PR Newswire
Deutsche Bank Adjusts Danaher Price Target to $240 From $250, Maintains Buy Rating - marketscreener.com
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns - Investing.com Canada
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026 - TIKR.com
Stifel cuts Danaher stock price target on bioprocess weakness By Investing.com - Investing.com Canada
Danaher (NYSE:DHR) Returns To Value Stock Focus After Results Update - Kalkine Media
Danaher revenue up 5.5% to USD 6.3B in Q2 2026 - Medical Buyer
Danaher Shares Drop 11% After Biotech Division Growth Falls Short of Expectations, Forcing Valuation Adjustment - TechStock²
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com
Wells Fargo Adjusts Price Target on Danaher to $195 From $212, Maintains Equalweight Rating - marketscreener.com
Danaher (DHR) Experiences Significant Decline - GuruFocus
Danaher Shares Slide 11% as Valuation Drops Following Biotech Growth Miss - TechStock²
Guggenheim Adjusts Price Target on Danaher to $200 From $235, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Danaher to $210 From $230, Maintains Buy Rating - marketscreener.com
Danaher (DHR) Reports Q3 Revenue Growth of 2%-3% Year-over-Year - GuruFocus
Don’t Quit on Danaher Stock After Horrific Earnings Reaction - Barron's
Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred - TradingView
DHR SWOT Analysis: Strong Financials Amidst Competitive Challenges Revealed in 10-Q Filing - GuruFocus
Danaher (DHR) Reports Strong Q2 Earnings, Stock Drops Due to Ord - GuruFocus
Danaher (DHR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Danaher Earnings Call Signals Growing Core Momentum - TipRanks
Danaher (DHR) Reports Strong Q2 2026 Results and Raises EPS Guid - GuruFocus
Danaher Corporation’s Stock Price Plummets to $179.01, Registering a Sharp 10.99% Drop - Smartkarma
Is Danaher Corp (DHR) a Bargain After 11.0% Drop? GF Value Says Undervalued - GuruFocus
Danaher (DHR) Experiences Notable Decline Amid Market Fluctuatio - GuruFocus
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet - Investor's Business Daily
Danaher (DHR) Reports Strong Q2 Earnings, Raises Full-Year Guida - GuruFocus
Danaher Posts Strong Q2 Results Driven By Life Sciences And Masimo Acquisition - insights.citeline.com
Danaher Corporation Provides Revenue Guidance for the Third Quarter 2026 - marketscreener.com
Why Danaher (DHR) Shares Are Falling Today - Yahoo Finance
Danaher (NYSE:DHR) in Focus on A Heavy Earnings Day For Healthcare - Kalkine Media
RBC Raises Danaher Price Target to $215 From $200 - marketscreener.com
Danaher Corp (DHR) Q2 2026 Earnings Call Highlights: Strong Reve - GuruFocus
Danaher Earnings Beat Estimates. Why the Stock Is Dropping Most Since 1991. - Barron's
Danaher stock stabilizes as diagnostics and life sciences support long term growth - Ad-hoc-news.de
Danaher beats Q2 earnings estimates but shares drop on biotech revenue worries - Pluang
Danaher plunges 13% on revenue outlook cut - Breakingthenews.net
Danaher's revenue outlook cut, biotech miss overshadow profit forecast lift - TradingView
DHR: Analyst Consensus Reaches $8.50 for Danaher Corporation - GuruFocus
Evercore ISI Adjusts Price Target on Danaher to $205 From $230 - marketscreener.com
Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip (NYSE:DHR) - Seeking Alpha
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y - TradingView
Danaher Corp (DHR) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
1.35%
大文字化:
|
ボリューム (24 時間):